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Background: Seropharmacology arising recently is a novel method of in vitro pharmacological study on Chinese
herb using drug-containing animal serum. As seropharmacology possesses the advantages of experiments in vitro
and in vivo, it is increasingly applied in pharmacological research on Chinese medicine. However, some issues of
seropharmacology remain controversial and need to be clearly defined. San Huang Yi Gan Capsule (SHYGC) is a
Chinese herbal formula with antiviral property against hepatitis B virus (HBV), but little is known about the
mechanism underlying its anti-HBV activity. The aim of the present study was to elucidate the action mechanism
of SHYGC using seropharmacological method and systematically address the methodology of preparing
drug-containing serum.
Methods: New Zealand rabbits were orally administrated SHYGC with various regimens, followed by preparation of
SHYGC-containing rabbit sera with a variety of methods. After HBV-producing HepG2 2.2.15 cells were treated with
SHYGC-containing sera or entecavir for 9 days, the levels of hepatitis B surface antigen (HBsAg) and HBV DNA and
the activity of DNA Polymerase were determined in HepG2 2.2.15 cells-conditioned media.
Results: An optimally standardized method of preparing drug-containing serum was raised for seropharmacology,
with which SHYGC was demonstrated to suppress HBsAg expression, HBV DNA replication and DNA Polymerase
activity in a dose-dependent fashion.
Conclusions: This seropharmacological study shows SHYGC is a potentially powerful anti-HBV agent. Additionally,
seropharmacology is a promising pharmacological method with a broad range of advantages, and it can be widely
used in biomedical research, if combined with pharmacokinetics.
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Seropharmacology is a novel method arising over the
relatively recent years for pharmacological study on
Chinese materia medica in vitro using drug-containing
serum [1-5]. The essence of seropharmacology is ad-
ministration of drug to experimental animal (rabbit, rat
or mouse), followed by harvest of animal blood and
conduction of in vitro pharmacological experiment with
the drug-containing animal serum. This pharmacological
method has the same advantages as the in vitro* Correspondence: haibo.xu@cdutcm.edu.cn
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reproduction in any medium, provided the orexperiment, for instance, convenient control of experi-
mental condition and exclusion of interference by internal
factors, which facilitate in-depth study on the action
mechanism of drug. More importantly, seropharmacology
reflects the internal process (absorption, distribution,
metabolism and excretion) of drug in the body, as the
drug contained in the animal serum is in the form of
bioactive metabolite with the truly pharmacological
potency of interest after internal biotransformation. By
building a bridge between the experiments in vitro and
in vivo, seropharmacology is a perfect combination of
the two experimental systems. As Chinese herb generally
features numerous components, complex metabolism
and multiple drug targets, it is an arduous task to clarifyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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can not represent the whole herb in respect of efficacy.
Therefore, seropharmacology is quite suitable to the
study on Chinese medicine, and it is increasingly employed
in pharmacological research on Chinese herb, especially
Chinese herbal formula [2-5], However, seropharmacology
maintains some elusive issues, particularly the method
of preparing drug-containing serum, which need to be
intensively elucidated.
Hepatitis B virus (HBV) is a major affliction which
burdens people globally [6]. Currently, the approved
therapies for HBV infection utilized in clinical setting
consist mainly of alpha interferon [7] and nucleoside
analogs, such as lamivudine [8] and entecavir (ETV)
[9]. However, these antiviral agents often give rise to
undesirable adverse reactions and their efficacies are
severely compromised in most patients by development
of antiviral resistance after prolonged therapy. Therefore,
there is an urgent need for the development of new
anti-HBV agents that are both safe and effective.
San Huang Yi Gan Capsule (SHYGC) is a traditional
Chinese herbal formula composed of the water soluble
extracts of 6 medicinal plants, including Radix scutel
lariae, Rheum palmatum L., Radix bupleuri, Radix astrag-
ali, Fructus schizandrae and Radix glycyrrhizae. SHYGC
shows remarkable potential of antiviral capability against
HBV without appreciable side effects, and it significantly
attenuates hepatitis B e antigen (HBeAg) level in the sera
of patients with hepatitis B [2]. However, the underlying
mechanism for anti-HBV activity of SHYGC has so far
remained unknown.
Here, we systemically addressed the methodology of
preparation of drug-containing serum and looked insight
into the mechanism underlying the anti-HBV capacity
of SHYGC using the seropharmacological method. More-
over, a standardized model is to hopefully set up for




San Huang Yi Gan Capsule (SHYGC) containing 1.67 g
of the water soluble extracts of 6 Chinese herbs, provided
by Institute for Chinese Materia Medica, Guangzhou
University of Chinese Medicine, was dissolved in double
distilled water (ddH2O) at 500 mg/ml. The authors are
prepared to supply SHYGC to anyone who wants to
replicate the study. Entecavir (ETV), derived from
Bristol-Myers Squibb Corporate (New York, NY), was
dissolved in 100% dimethyl sulfoxide at 10 μM as a stock.
Prior to experimental tests, ETV was diluted in cell culture
medium, with working concentration of 10 nM. 3H-dTTP
was supplied by PerkinElmer NEN Inc. (Massachusetts,
USA). All other reagents were commercially available.Preparation of SHYGC-containing rabbit sera
All animal experiments were carried out in strict accord-
ance with the China Experimental Animal Act 1988, and
all animal research procedures were approved by the
Research Ethics Committees of Guangzhou University of
Chinese Medicine and Chengdu University of Traditional
Chinese Medicine. New Zealand white rabbits weighing
2.0 ± 0.2 kg each were randomly arranged in 4 groups
of 2 male and 2 female rabbits, and housed at one per
cage in a ventilated, temperature- and humidity-controlled
animal facility with 12 h light-12 h dark cycle, and fed
with standard diet and distilled water ad libitum.
Rabbits of low, medium and high dose SHYGC groups
were gavaged SHYGC in doses of 0.25 g/kg, 0.5 g/kg
and 1.0 g/kg daily, while rabbits of vehicle group were
gavaged the volume-matched ddH2O. Dose selection
was based upon our previous study, in which SHYGC
treatment significantly reduced HBeAg level in the sera
of patients with hepatitis B [2]. SHYGC of daily dosage
was divided into equal shares and given to rabbits once,
twice or thrice per day for 7 days. On day 8, after 12 h
of fasting, rabbits were subject to last administration. At
0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h and 4 h post-
administration, blood were retrieved from rabbits, via
ear artery or transcardial puncture, with anesthesia by
injection of pentobarbital sodium at a dose of 40 mg/kg
in the marginal ear vein. Then, sera were collected by
centrifugation of blood at 2000 × g for 10 min at 4°C,
and some of sera were heat-inactivated at 56°C for 30 min.
Finally, all of rabbit sera were sterilized by filtration
through 0.22 μm cellulose ester membranes.
HepG2 2.2.15 cells culture and treatment
HepG2 2.2.15 cells were originally obtained from George
Acs (Mount Sinai Medical Center, New York, N.Y.) and
capable of constitutively producing and secreting HBV
viral particles [10]. The cells were seeded on 24-well
plates at 5 × 104 cells per well and grown in 1 ml of
minimal essential medium (MEM) supplemented with
10% fetal bovine serum, 380 μg of G418 per ml, 50U of
penicillin per ml and 50 mg of streptomycin per ml in
5% CO2 atmosphere at 37°C. Forty eight hours post
seeding, the cells approached 80% confluency and were
treated for 9 days by 1 ml of MEM containing 2% fetal
bovine serum, 380 μg of G418 per ml, 50U of penicillin
per ml, 50 mg of streptomycin per ml, and 0.2 ml of
SHYGC-containing rabbit sera, 0.2 ml of rabbit serum
vehicle, or ETV at 10 nM. On day 10, the culture media
conditioned by HepG2 2.2.15 cells were harvested and
clarified by a 5-min centrifugation at 1000 × g at 4°C. The
resultant supernatant media were processed for determin-
ation of hepatitis B surface antigen (HBsAg) expression,
HBV DNA polymerase activity and HBV DNA level as
below. Each test was performed in 8 wells in parallel.
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Fifty microliters of above HepG2 2.2.15 cells-conditioned
media were added on 96-well plates coated with anti-HBs
(antibody to HBsAg), and underwent the measurement
of HBsAg expression with enzyme-linked immunosorb-
ent assay (ELISA) kits (Yueliangwan Biotechnology Co.,
Shenzhen, China), as per the manufacturer's specifications.
HBsAg level was expressed as the value of sample (P)
against negative control (N), represented by the ratio of
sample OD450nm (optical density at 450 nm) value to
negative control OD450nm value.Specific immunoprecipitation assay of HBV DNA
polymerase activity
The HBV DNA polymerase (Pol) activity was sought in
the above conditioned media by a minor modification of
the specific immunoprecipitation method [11]. Briefly,
400 μl of samples were placed into tubes of test and blank
control. After excessive anti-HBs were added, mixtures
were incubated at 37°C for 60 min, followed by two
washes with Tris–HCl buffer (0.2 M, pH 7.5). In test
tubes were added 20 μl of 1 mg/ml pronase E, 20 μl of
0.2 M Tris–HCl buffer (pH 7.5) containing 1.5% NP-40
and 0.4% β-mercaptoethanol, and 20 μl of substrate
containing 0.08 M MgCl2, 0.24 M NH4Cl, 1 mM of
dATP, dCTP and dGTP each and 0.5 μCi 3H-dTTP. In
blank control tubes, 20 μl of above substrate and 40 μl
of 0.2 M Tris–HCl buffer (pH 7.5) were added. After
incubation at 37°C for 4 h, the reaction mixtures were
spun, and 50 μl of supernatants were spotted on glass fiber
filters and assayed for trichloroacetic acid-precipitable
radioactivity by scintillation counting. CPM (counts per
min) values for test tubes were obtained by subtraction
of those for blank control tubes.Dot blot hybridization assay of HBV DNA level
The detection of HBV DNA level in the above condi-
tioned media was conducted with a non-radioactive dot
blot hybridization assay (Xieheng Bioengineering Co.,
Shanghai, China), in light of the product handbook.
Briefly, 50 μl of samples were applied to nitrocellu-
lose membranes, followed by denaturation for 20 min.
Then, the membranes were baked at 80°C for 1 h and
prehybridized for 2 h at 42°C. After hybridization with
digoxigenin-11-dUTP-labled probe DNA at 42°C for
24 h, the membranes were blocked by bovine serum
albumin for 20 min at 42°C. The hybridized products
were next detected by adding anti-digoxigenin-alka-
line phosphatase antibody and the specified substrate.
Blue-purple colors were precipitated in few minutes,
and HBV DNA level was evaluated as percentage of
the control.Statistical analysis
Data obtained in this study were processed to determine
means and standard errors, and presented as mean ± SEM
(standard error of the mean). The statistical significances
between the mean values were assessed by one-way
analysis of variance (ANOVA) or Student’s t-Test with
SPSS software. A value of P < 0.05 was considered statisti-
cally significant.
Results
The methodology of preparing drug-containing serum
We systematically studied the methodology of preparing
drug-containing serum. First, the influence of serum
itself on the result of pharmacological experiment was
probed. We found that inactivated rabbit serum had no
effect on HBsAg level in HepG2 2.2.15 cells-conditioned
media, while non-inactivated serum significantly dimin-
ished HBsAg expression (Figure 1A). To preclude the
effect of rabbit serum vehicle on HBV, all of rabbit sera
containing or not containing SHYGC underwent inactiva-
tion at 56°C for 30 min, prior to the following experimental
tests.
Given the same daily dosage, we wondered whether
the administration regimen was a factor to affect the
experimental result. Although all of medium dose SHYGC-
containing rabbit sera reduced HBsAg expression, the
potencies of drug-containing sera prepared by adminis-
tration twice daily and thrice daily were higher than
that of once per day. Additionally, no differences in the
actions on HBsAg level were noted between twice daily
and thrice daily (Figure 1B). In the following research,
to facilitate the administration, rabbits received twice-a
-day dosed treatment in the morning and at night to
produce SHYGC-containing sera.
The approach of harvesting drug-containing sera from
rabbits was then explored. Medium dose SHYGC-con-
taining rabbit sera retrieved via ear artery and transcardial
puncture both markedly lowered HBsAg expression,
and drug-containing sera collected by these two methods
revealed similar potency (Figure 1C). In the following
experiments, for convenience of blood collection, drug-
containing sera were harvested from rabbits via ear artery.
Finally, the optimal time point for collecting SHYGC-
containing sera was determined. Medium dose SHYGC-
containing sera harvested at all time points of 0.5 h to
4 h post-final administration displayed significant inhib-
ition on HBsAg expression. While drug-containing sera
collected at 2 h post-final administration exerted the
strongest efficacy (Figure 1D). In the following assays, to
obtain the highest potential of SHYGC, drug-containing
sera were collected at 2 h post-final dose.
Consequently, an optimal and relatively standardized
method was established to prepare drug-containing serum
for seropharmacological research. In summary, drug of
Figure 1 Effects of SHYGC-containing rabbit sera, prepared with various methods, on HBsAg level in HepG2 2.2.15 cells-conditioned
media. Panel A, inactivated rabbit serum had no effect on HBsAg level in the conditioned media, while non-inactivated serum significantly
mitigated HBsAg expression (* P < 0.05 versus Control and Inactivated Serum). Panel B, rabbit sera containing medium dose of SHYGC
administrated with various regimens inhibited HBsAg expression (* P < 0.05 and ** P < 0.01 versus Serum Vehicle), and the potencies of
SHYGC-containing sera prepared by administration twice daily and thrice daily were higher than once daily († P < 0.05). Panel C, medium
dose SHYGC-containing rabbit sera harvested via ear artery and transcardial puncture both reduced HBsAg expression (** P < 0.01 versus
Serum Vehicle). Panel D, medium dose SHYGC-containing sera collected at various time points after the final dose all attenuated HBsAg
expression (* P < 0.05 and ** P < 0.01 versus Serum Vehicle).
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orally given to rabbits twice per day, in the morning
and at night, for 7 consecutive days. On the 8th day,
2 h after the final administration, the rabbit sera was
harvested via ear artery and subject to heat-inactivation at
56°C for 30 min. This comprehensive method of producing
drug-containing serum was applied to all assays below.
SHYGC-containing sera inhibits HBsAg expression
Subsequently, we detected the effect of SHYGC on HBsAg
level in HepG2 2.2.15 cells-conditioned media, using
the above seropharmacological method. Compared to
rabbit serum vehicle, rabbit sera containing SHYGC at low,
medium and high does all attenuated HBsAg expression,
and the inhibitory potential of SHYGC showed dose
dependent. However, ETV did not significantly alter
the HBsAg expression (Figure 2).SHYGC-containing sera inhibits HBV DNA Pol activity
In order to deeply elucidate the antiviral property of
SHYGC against HBV, the action of SHYGC on HBV
DNA Pol activity was assessed with a modified specific
immunoprecipitation assay. Except low dose, rabbit sera
containing medium and high doses of SHYGC and ETV
all inhibited HBV DNA Pol activity, compared to the
control and rabbit serum vehicle. The suppression of
DNA Pol activity by SHYGC was in a dose-dependent
manner. In addition, treatment with high dose SHYGC-
containing sera and ETV did not significantly differ in
the inhibition of DNA Pol activity (Figure 3).
SHYGC-containing sera inhibits HBV DNA replication
The appreciable effect of SHYGC on HBV DNA Pol
activity drove us to further explore the potency of SHYGC
on HBV DNA replication. We found that rabbit sera
Figure 4 Effects of SHYGC-containing rabbit sera, prepared
with the optimal method, on HBV DNA level in HepG2 2.2.15
cells-conditioned media. Sera containing medium and high doses
of SHYGC and ETV alleviated HBV DNA replication (* P < 0.05 and
** P < 0.01 versus Control and Serum Vehicle), and this sort of efficacy
of SHYGC was in a dose-dependent fashion (# P < 0.05 versus Low
Dose and High Dose). High does SHYGC and ETV exhibited no
differential potentials on the down regulation of DNA replication
(‡ P < 0.01 versus ETV).
Figure 2 Effects of SHYGC-containing rabbit sera, prepared with
the optimal method, on HBsAg level in HepG2 2.2.15 cells-
conditioned media. Sera containing SHYGC at low, medium and
high does all decreased HBsAg expression (* P < 0.05 and ** P < 0.01
versus Serum Vehicle), and the inhibitory potential of SHYGC showed
dose dependent (# P < 0.05 versus Low Dose and High Dose).
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all lessened HBV DNA replication, compared to the
control and rabbit serum vehicle. However, HBV DNA
replication was not affected by low dose SHYGC-
containing sera. The inhibition of DNA replication by
SHYGC was in a dose-dependent pattern. Moreover, no
difference in down regulation of DNA replication was
noted between high does SHYGC and ETV (Figure 4).
Discussion
One of the most annoying problems for pharmacological
study is that the data of in vitro experiment sometimes
differs greatly from that of in vivo test. The reasons forFigure 3 Effects of SHYGC-containing rabbit sera, prepared
with the optimal method, on HBV DNA Pol activity in HepG2
2.2.15 cells-conditioned media. Sera containing medium and high
doses of SHYGC and ETV all blunted HBV DNA Pol activity (* P < 0.05
and ** P < 0.01 versus Control and Serum Vehicle), and this kind of
effectiveness of SHYGC was in a dose-dependent manner (# P < 0.05
versus Low Dose and High Dose). Treatment with high dose SHYGC-
containing sera and ETV did not differ in the inhibition of DNA Pol
activity (‡ P < 0.01 versus ETV).this problem may include the poor absorption of drug in
the digestive track, biotransformation of drug to active
metabolite only in the body, inactivation of compound
during metabolism, and indirect action of drug through
release of internal factors, such as endogenous hormone,
cell factor, antibody, complement, and so forth. For
Chinese herb, conventionally in vitro pharmacological
method is addition of the soluble extract of medicinal
plant in its original pharmaceutics to in vitro test system,
such as cells, tissues, viruses, organs, etc. However, some
flaws of this type of research method are always con-
cerned. First, the pharmaceutical constituents (chemical,
ion, pH value, impurity and osmotic pressure) are bound
to alter the experimental condition. Second, in the original
pharmaceutics may be not the truly active component
after internal biotransformation and metabolism. Third,
the pharmacological data from this in vitro experimental
system should be validated as false positive and false
negative results are likely displayed. Efforts have been
made in recent years to resolve these above concerns with
seropharmacology, which is to perform pharmacological
experiment in vitro with drug-containing animal serum,
which retains the real metabolite after physical biotrans-
formation, and reflects the drug absorption into blood
stream, internal metabolism and indirect action through
endogenous factors. Seropharmacology also precludes the
interference of pharmaceutical constituents on experimen-
tal outcome and promote the reliability of research data.
Furthermore, seropharmacology is more benefiting to
the study on Chinese herb, especially the Chinese herbal
formula, that generally features the characters of complex
components, multiple targets and various functions. Taken
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and a novel approach to pharmacological research of
Chinese medicine, and possibly western medicine as
well, by bridging the experiments between in vitro and
in vivo.
The most important issue for seropharmacology is
the preparation of drug-containing animal serum which
has been highly controversial since the emergence of
seropharmacology. Attempts were made in this report to
set up an optimally standardized method of preparing
drug-containing serum. According to this method, the
selection of animal to treat with drug was on the basis
of the amount of blood the animal can provide. Rather
than rats and mice, rabbits that can offer more blood were
recruited to produce SHYGC-containing sera. In addition,
the twice-a-day and thrice-a-day dosed medications
were more potent than once-a-day dosed medication,
which may be due to single dose of large amount of drug
exceeding the capability of absorption in gastrointestinal
tract. With this method, serum drug concentration
seemed to reach the steady state (Css) after 7 consecutive
days of administration, because all of medium dose
SHYGC-containing sera obtained at various time points
significantly lessened HBsAg expression, although the
exact concentration of the herbal formula in rabbit sera
was not measured, mainly due to the technical problem.
Nowadays, the main anti-HBV agents approved by World
Health Organization are nucleoside analogs and costly
alpha interferon, which commonly show poor effects
on drug-resistant mutated HBV and cause adverse reactions
and rebound of HBV following the cessation of medication.
Nucleoside analogs, such as lamivudine and ETV, exert
the function of anti-HBV, chiefly by inhibition of HBV
DNA replication, while no direct action is clearly con-
firmed on the expression of HBsAg and HBeAg, which are
indicative of HBV infection and multiplication respectively
[12]. Chinese herbs have been demonstrated recently to
possess some advantages in the therapy of anti-HBV.
For instance, HBeAg and HBV DNA are under negative
seroconversions in chronic hepatitis B patients treated
by Radix astragali, one of the herbs in SHYGC [13].
Radix scutellariae, another herb of SHYGC, suppresses
both wild-type HBV and lamivudine-resistant mutated
HBV gene expression and virus production in human
hepatoma cells [14]. Based on our previous discovery
that SHYGC is a potential anti-HBV agent by reducing
HBeAg level in the sera of patients with hepatitis B, we
showed that SHYGC dose-dependently diminished the
expression of HBsAg, HBV DNA Pol activity and HBV
DNA replication, which is in agreement with other reports
on some herbs of SHYGC. For example, Radix astragali
and Fructus schisandrae effectively blunt HBsAg expres-
sion in HepG2 2.2.15 cells and hepatocellular carcinoma
cells respectively [15,16]. Rheum palmatum L. inhibitsHBV DNA replication and DNA Pol activity in HepG2
2.2.15 cells [17,18]. Being a positive control, ETV, a
guanosine nucleoside analogue with the activity against
HBV reverse transcriptase, in this study drastically lowered
HBV DNA replication and DNA Pol activity in HepG2
2.2.15 cells, consistent with previous reports [19-21], while
no significant effect on HBsAg level was observed. In
contrast, SHYGC presents a broad range of advantages
by significantly suppressing the expressions of HBsAg
and HBeAg, HBV DNA replication and DNA Pol activity,
and it appears to be a promising candidate of HBV inhibi-
tor in clinical practice. Concomitantly, seropharmacology
was validated in our study to be applicable in pharmaco-
logical research of Chinese medicine.
Nevertheless, in this study inevitably remain some lim-
itations, which should be under particular consideration.
First, SHYGC concentration in rabbit sera was just
assumed to attain the steady state (Css) at the time of
collecting drug-containing sera, which was based on
the principle of pharmacokinetics, in which serum drug
concentration is gradually elevated to Css by multiple
doses. Typically, if dosing interval is drug half-life (t1/2),
the serum drug concentration will achieve Css in 5 to
7 t1/2 s. However, it is extremely difficult to obtain the
exact t1/2 of SHYGC, that is composed of 6 Chinese
herbs and a number of bioactive components with various
t1/2 s, although the pharmacokinetics investigation of
SHYGC would be supplementary to this study. On the
other hand, Css is not essential for seropharmacological
study, although the higher serum drug concentration is
absolutely beneficial to the research. Second, in serophar-
macological study including our research, healthy animals
are commonly recruited to prepare drug-containing sera
[1-5], but the animals with specific disease should be
superior to healthy animals for this point, because the
internal process of drug in animals with disease of
interest is more close to that in human patients, and
animals of disease model could differ significantly from
healthy animals in the biotransformation and metabolism
of drug, which may be a critical factor to influence the
ingredients of drug-containing serum. However, there
is a long way to go to establish various animal models
of specific disease for seropharmacological research.
Third, notwithstanding seropharmacology is a combin-
ation of in vivo and in vitro tests, it can not entirely
represent the study in vivo, because the true effectiveness
of drug in the body may be affected by other factors, such
as the level of drug receptor in the body, the affinity of
drug to receptor, the physical response to drug, etc.
Conclusions
Taken together, the antiviral property of SHYGC against
HBV is strongly underpinned, which merits further
investigation of the action mechanism and rigorously
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standardized model for seropharmacological research is
established, and seropharmacology is shown to be a
promising method for pharmacological study on drugs,
in particular Chinese medicine. Combining with pharma-
cokinetics, seropharmacology can be broadly applied in
biomedical research with bright prospect.
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